Trial shows vaccine against cervical cancer provides long-term protection

A vaccine against the virus that causes cervical cancer could protect women for up to four and half years, according to a study published online today (Thursday April 6, 205) by The Lancet.

Cervical cancer is the second most common cancer in women worldwide. Persistent infection with the human papillomavirus (HPV) is the main cause of the disease. The most common HPV types associated with the disease are HPV-16 and HPV-18. In a trial in 2004, Diane Harper (Dartmouth Medical School, Hanover, NH, USA) and colleagues found that a vaccine against these viruses could prevent cervical cancer, but its long-term effectiveness and safety was unclear.

To investigate, Dr Harper's team followed-up 800 women from the original trial who had received three doses of the HPV-16/HPV-18 vaccine or placebo. The researchers found that women given the vaccine had sustained high levels of antibodies against HPV-16 and HPV-18 for up to 4.5 years after receiving the last dose of the vaccine. The antibody levels did not decrease as is commonly seen at 4 years in other vaccines, state the authors. The team found that the vaccine was effective against persistent and new infections and protected against infection with HPV-45 and 31--the third and fourth most prevalent oncogenic types of HPV. The vaccine also had a good long-term safety profile and provided substantial long-term protection against cancerous cell changes associated with high-risk HPV types.

Dr Harper states: "These findings set the stage for the widescale adoption of HPV vaccination for prevention of cervical cancer."


Contact: Udani Samarasekera

Page: 1

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Trials underway for essential new TB vaccine
3. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
4. ENDEAVOR III Trial reports key findings on new-generation stent
5. NIH names Clinical Trial Units for the Microbicide Trials Network
6. Clinical Trials Units selected for newly restructured HIV/AIDS research networks
7. The Public Library of Science launches the new open access journal PLoS Clinical Trials
8. Trial shows malaria vaccine could protect young children from disease for 18 months
9. Trial demonstrates new drugs effectiveness against psoriasis
10. Trial at Jefferson shows new drug may help cancer patients who need stem cell transplants
11. Second implant of US Pilot Trial achieved

Post Your Comments:

(Date:7/13/2019)... ... July 12, 2019 , ... ... launch of its proprietary patient management platform, Ospitek “View”. Ospitek has partnered with ... to deliver a fully customizable, intelligent, solution made specifically for surgical centers, allowing ...
(Date:7/13/2019)... ... , ... The American Med Spa Association (AmSpa) has released the 2019 Medical ... and medical spa professionals understand the realities of the industry and make better, more ... years since AmSpa released the 2017 Medical Spa State of the Industry Report and ...
(Date:7/11/2019)... ... July 11, 2019 , ... Swagelok Southeast Texas, ... its territory through the acquisition of another Houston-area distributor. The acquisition of the ... facilities located in LaPorte, Nederland and Houston. , With this expansion, Swagelok ...
(Date:7/10/2019)... ... ... Foggiare --the first and only U.S. company to offer Slim-Up treatments--is now ... by Sauna Italia , an Italian manufacturer of advanced aesthetic and wellness equipment, ... locations in Europe and Asia. Slim-Up is scientifically proven to be effective in smoothing ...
(Date:7/10/2019)... ... July 10, 2019 , ... Given that ... Grove Fertility (SGF) remains committed to its core mission of fertility education ... of July, the practice will host six in-person seminars and three virtual webinars ...
Breaking Medicine News(10 mins):
(Date:7/11/2019)... , ... July 11, 2019 , ... ... GRM Information Management, a leading provider of enterprise content management solutions, will exhibit ... Lick, Indiana July 17 to July 19. , Conference attendees are encouraged ...
(Date:7/10/2019)... ... July 10, 2019 , ... ... published randomized, double-blind, placebo controlled clinical study from Ohio State University Wexner ... humic substance containing urolithins, fulvic acid, and micro minerals. Natreon is committed ...
(Date:7/10/2019)... , ... July 10, 2019 , ... DidCBDWork.com ... world for the past 18 months, does CBD actually work? It seems like depending ... snake oil. , DidCBDWork.com instead aims to get testimonials of real CBD users, ...
Breaking Medicine Technology:
Cached News: